Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Prostate Adenocarcinoma AJCC v7: early-phase trial registry
A small indexed set (8 trials) with no open enrollment listed right now.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count
Stage IV Prostate Adenocarcinoma AJCC v7: 8 US clinical trials tracked, none currently recruiting.
Stage IV Prostate Adenocarcinoma AJCC v7 is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition stage-iv-prostate-adenocarcinoma-ajcc-v7
OPEN 0 | RECR 0% | LATE 0 | EARLY 8 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Stage IV Prostate Adenocarcinoma AJCC v7 has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Prostate Adenocarcinoma AJCC v7 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Prostate Adenocarcinoma AJCC v7 is recruiting below its size-band peers.
0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Prostate Adenocarcinoma AJCC v7 research.
M.D. Anderson Cancer Center accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Stage IV Prostate Adenocarcinoma AJCC v7 enrolment sits around 190 participants.
Median target enrolment is 190 among the 8 trials that report a genuine target (sentinel values excluded). 4 of those (50%) plan for fewer than 100 participants.
-
Stage IV Prostate Adenocarcinoma AJCC v7 research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NRG Oncology
NCT03371719
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
ECOG-ACRIN Cancer Research Group
NCT03419234
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT02703623
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
Yale University
NCT03456843
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
NCT02893917
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
NCT00544830
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
NCT01409200
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
OHSU Knight Cancer Institute
NCT02099864
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Prostate Adenocarcinoma AJCC v7 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Prostate Adenocarcinoma AJCC v7 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Prostate Adenocarcinoma AJCC v7 page
8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Stage IV Prostate Adenocarcinoma AJCC v7 trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- M.D. Anderson Cancer Center sponsors the most Stage IV Prostate Adenocarcinoma AJCC v7 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Prostate Adenocarcinoma AJCC v7 condition card totals 8 registered trials; most-linked intervention Cabazitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.